Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant diseases with 55,440 new cases in the USA each year [1] . Even with a low rate of new cases, the 7% 5-year survival rate makes pancreatic cancer the fourth leading cause of cancer-related death, and this 7% rate has not increased in the last 20 years [1] [2] [3] [4] . PDAC is mostly treated by surgery, radiation, and chemotherapy, but only 15-20% of the patients can be successfully resected after diagnosis [5] [6] [7] . The lack of an effective therapy and the fact that PDAC is mostly diagnosed in advanced stages because of unspecific or late symptoms shows the need for screening programs for those high-risk individuals [8] [9] [10] . This is especially true for the 10% of diagnosed patients showing a familial background [11] [12] [13] .
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant diseases with 55,440 new cases in the USA each year [1] . Even with a low rate of new cases, the 7% 5-year survival rate makes pancreatic cancer the fourth leading cause of cancer-related death, and this 7% rate has not increased in the last 20 years [1] [2] [3] [4] . PDAC is mostly treated by surgery, radiation, and chemotherapy, but only 15-20% of the patients can be successfully resected after diagnosis [5] [6] [7] . The lack of an effective therapy and the fact that PDAC is mostly diagnosed in advanced stages because of unspecific or late symptoms shows the need for screening programs for those high-risk individuals [8] [9] [10] . This is especially true for the 10% of diagnosed patients showing a familial background [11] [12] [13] .
Pancreatic cancer develops from low-grade lesions, which can progress through different stages up to high-grade lesions and invasive cancer [7, 14] . These precursor lesions are termed pancreatic intraepithelial neoplasia (PanINs), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN) [11, 15, 16] . Cancer syndromes like Peutz-Jeghers Syndrome (PJS) or familial atypical multiple mole melanoma (FAMMM) syndrome can raise the risk of developing pancreatic cancer [17, 18] .
Since the background of familial pancreatic cancer (FPC) is known, several screening programs are available for patients who have a higher risk of developing PDAC [19, 20] . The International Cancer of the Pancreas Screening (CAPS) Consortium developed guidelines for screening and management of patients with higher risk or predisposition for pancreatic cancer [21] . This risk is defined as 2 or more first-degree relatives with pancreatic cancer [11] . Additionally, patients with a tumor syndrome and mutations that are connected to a higher risk of PDAC are included [21] . Not all factors are genetic, environmental influences like smoking or obesity can also promote the development of PDAC [22] .
These screening programs collect data to generate more knowledge about origin, development, genetic background, tumor cell 
Summary
Familial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.
and stroma interaction, diagnosis, and therapy of pancreatic cancer [19, 21, 23] . They also screen for non-invasive precursor lesions, which can be further observed or resected to avoid the development of cancer and improve the survival of high-risk individuals [19] . Typical screening methods include magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) [24] .
This review summarizes the current standard and knowledge about screening procedures including: screening centers, methods, inclusion of patients with familial background, and consequences and treatment options.
Definition
FPC cases include individuals with 2 or more first-degree relatives with pancreatic cancer who do not have any other inherited tumor syndrome [25] . The National Familial Pancreas Tumor Registry at Johns Hopkins showed that those people with 2 first-degree relatives have a 6.4-fold higher risk for developing PDAC, those with at least 2 first-degree relatives have a 9-fold risk [26] . If the individual has more than 3 first-degree relatives with this disease, the risk of PDAC rises to 32-fold [26] .
Phenotype and Pathology
PDAC can develop earlier in patients with predispositions, and risk is increased by environmental stimuli like smoking or alcohol abuse [11] . It is not clear if hereditary pancreatic cancer death always occurs earlier than sporadic pancreatic cancer death [11, 27, 28] . However, the 10% of patients with familial PDAC develop more precursor lesions compared to people without familial predisposition [29, 30] . Some predispositions only stimulate the development of PDAC (around 40%) such as hereditary pancreatitis, whereas others include different types of cancer (around 60%) like hereditary breast and ovarian cancer [11, 27, 31] Lesions such as PanINs, IPMN, and MCN can be detected and treated to avoid the development of invasive lesions [11, 15, 16] . Most mouse models show a transdifferentiation of acinar cells and development of PanIN1a, PanIN1b (low-grade lesions), PanIN2 (intermediate-grade lesions), and PanIN3 (high-grade lesions) in a linear process; however, pancreatic cancer can also develop without a step up process of PanIN lesions [15, 22, 32, 33] . More investigations are necessary to gain a better understanding of these processes and mechanisms.
Recently, subclassifications have been performed to improve diagnosis, answer questions about prognosis and consequences in therapy [34] [35] [36] . 4 subtypes are defined by expression analysis with correlation to histopathology: squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX) [35, 37] . So far, it is not clear which subtypes with histological and transcriptional characteristics are connected to which familial background, so that more investigation is necessary and important. Nevertheless, multifocal precursor lesions can be found in patients with an FPC background, suggesting that screening of those patients could be advantageous to early detection of dangerous lesions [11, 38, 39] .
Genes, Syndromes, and Risk Factors
The familial background of PDAC is connected to mutations in important genes. Mutations in these genes can lead to the development of this type of tumor, and are explained below. These affected genes are listed in figure 1 and are connected to different cancer syndromes.
Hereditary cancer syndromes represent one of the most important risk factors for the development of pancreatic cancer. The group of tumor syndromes includes the autosomal dominant PJS with mutations in the tumor suppressor gene LKB1/STK1 on chromosome 19, which usually regulates energy coupling, cell division, and growth [17] . The risk of developing PDAC with this mutation is around 35% [25, 40, 41] . FAMMM is another autosomal dominant syndrome with mutations in the tumor suppressor CDKN2a and has a life time increased risk for PDAC of around 17% [18] . CDKN2A is normally important for the cell cycle and has influence on CDK4, CDK6, p53, and Mdm2 with its gene products p16 and p14 [42] . Hereditary breast and ovarian cancer (HBOC) syndrome is associated with mutations in BRCA1/2 in 25% of cases and a life time risk of 3-8% for developing PDAC [11, 43, 44] . The most important role of BRCA1/2 in normal tissue is in the response to DNA damage, e.g. the induction of apoptosis or blockage of proliferation [45] . Li-Fraumeni syndrome with TP53 mutations is autosomal dominant with a life time increased risk for pancreatic cancer of around 5-8% [25, 46] . p53 is called the guardian of genome because of its role as a transcription factor in cell survival and death [47] . Hereditary nonpolyposis colecrectal carcinoma syndrome (HNPCC)/Lynch Syndrome shows mutations in MLH1, MSH2, MSH6 or EPCAM, and is autosomal dominant with a risk of around 3.7% for developing PDAC [48, 49] . MLH1, MSH2, and MSH6 are important in the context of DNA mismatch repair [50] . EPCAM is involved in cell-matrix or cell-cell adhesion [51] . Familial adenomatous polyposis (FAP) is also autosomal dominant and contains mutations in APC, which is connected to the WNT signaling; the risk for developing PDAC with FAP is lower than 5% [11, 52, 53] . Ataxia telangiectasia (ATM) is autosomal recessive and the life time risk is also less than 5% for developing PDAC [25, [54] [55] [56] . ATM is connected to DNA damage response [57] .
Hereditary diseases that are associated with chronic inflammation/dysfunction of the gland also show an association with PDAC. Hereditary pancreatitis is autosomal dominant, has a high life time risk of 40% for developing PDAC, and is associated with mutations in PRSS1 and SPINK1 [58] [59] [60] . PRSS1 is a serine protease and SPINK1 encodes for a trypsin inhibitor in the healthy pancreas [59, 61] . Cystic fibrosis as an autosomal recessive disorder has mutations in CFTR and shows a life time risk of around 5% for PDAC [62] [63] [64] . CFTR is a ductal anion channel and has the role of generating fluid to bring activated trypsin in the pancreatic ducts [61] . Mutations in, amongst others, BRCA2, PALB2 (which is a partner of BRCA2), and ATM can be seen in the FPC syndrome and show a life time risk of around 40% for PDAC [11, 65] .
These predispositions can be escalated by other environmental influences such as smoking [66] . Additional risk factors for developing PDAC can be caused by demographic changes or environment [26] . In general, the life time risk for developing PDAC is 1.49% and increases with age [67] . Although it is not known why, women who have their first child at an older age have an increased risk for pancreatic cancer [68] . Smoking and alcohol abuse, especially seen in heavy drinkers, increases the risk of developing pancreatic cancer [22] . 20-35% of cases with PDAC are associated with smoking [67] . Obesity, as shown by BMI, as well as diabetes mellitus lead to an increased risk for PDAC [22, 69, 70] . Pancreatitis is one of the most important risk factors for PDAC [71] . People with cholecystectomy, gastrectomy or Helicobacter pylori infection also have a higher risk of developing PDAC [67, 72, 73] .
Procedure of Screening

Centers and Methods for Screening
Specialized centers for screening pancreatic cancer in high-risk individuals have been established in many parts of the world. These centers include an FPC registry, which aids screening programs, with the aim of finding the cause of PDAC and developing better treatment options using the collected data [19] . Before the establishment of these centers, Lynch and colleagues [20, 27] started a study with families who suffer from pancreatic cancer. This study highlighted the need for a special focus on high-risk individuals.
The first centers founded for screening of high-risk individuals were the National Familial Pancreas Tumor Registry (NFPTR) at Johns Hopkins University in 1994, the European Registry of Hereditary Pancreatitis and Familial Pancreas Cancer (EUROPAC) at Liverpool University in 1997, and the German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa) at Philipps University Marburg in 1999 [19, 27, [74] [75] [76] . After this, more centers in Japan (Kyoto University, Japanese Familial Pancreatic Cancer Registry), USA (17 centers), Canada (Mount Sinai Hospital, Toronto, Familial Gastrointestinal Cancer Registry), Europe (Germany, Italy, Spain), and Australia (The Kinghorn Cancer Center, Australian Pancreatic Cancer Genome Initiative) have been established [19] . Of course, it is important that specialized screening centers are available for all patients, especially those who have limited access to healthcare [77] .
Pancreatic cancer typically does not show symptoms until the advanced stages, and symptoms of advanced pancreatic cancer can be pain, fatigue, loss of appetite or psychological distress, which are based on malignancy and infiltration [26, [78] [79] [80] [81] . Therefore, additional screening options are necessary for high-risk individuals. In general, biomarkers for PDAC can include genomics, epigenomics, non-coding RNAs, metabonomics, liquid biopsies, and microbiomes in several body fluids such as urine or plasma [82] . Biomarkers such as CA19-9 are mainly used for disease monitoring but not for screening, and more effective and validated biomarkers are needed [26, 82, 83] . Newly found biomarkers such as AHNAK2 or THBS2, which are potentially successful diagnostic markers, need to be involved in studies to show their effects in screening programs [84] [85] [86] . Additionally, biomarkers like Glypican-1, CD63, and miR-451a exosomes seem to be promising [87] [88] [89] . Nevertheless, in the development of successful biomarkers, it needs to be noted that predispositions such as chronic pancreatitis and pancreatic cancer may have different genetic abnormalities [90] .
The most commonly used techniques for screening are based on imaging, which is not always useful for lesions of < 1 cm [25, 26] . Methods such as EUS, MRI, magnetic resonance cholangiopancreatography (MRCP), computerized tomography (CT), multi-detector CT (MDCT), and endoscopic retrograde cholangiopancreatog-raphy (ERCP) are used. EUS and MRI are better options compared to CT [91] . EUS is advantageous because it is able to detect lesions of < 1 cm depending on the operator's experiences [19, 46] . EUS fine needle aspiration cytology (EUS-FNAC) is useful for investigating abnormal areas with high accuracy [25] . Positron emission tomography with 2-deoxy-2[ 18 F]fluoro-D-glucose (FDG-PET) is more accurate compared to MDCT and MRI [92] .
Population Screened
Because of the low incidence of PDAC, a population-based screening is not possible [2, 80] . All people with the genetic background (e.g. predispositions because of syndromes) that increases the risk of developing PDAC to over 5% and with at least 2 firstdegree relatives with PDAC should be involved in screening programs [11, 21, 93] .
Critical Lesions
Critical lesions such as T1N0M0 adenocarcinoma and high-risk PanIN3 lesions should be focused on during screening [11] . IPMN lesions should also be detected, including main-duct (MD-IPMN) and branch-duct (BD-IPMN) lesions [11] . Additionally, changes such as slight dilatation of the main pancreatic duct, inflammatory processes, and small cystic lesions can be indications for developing PDAC [26, 94] .
Start and Frequency of Screening
So far, the questions of age at initial screening and the frequency have not been completely answered since the behavior of PDAC, progression, and origin are not well understood [26, 95] . Most programs start screening for patients at the age of 40 years, which is based on the youngest age noted for FPC or, alternatively, 10 years below the youngest age of onset within the family [2, 11, 91] . The screening is repeated every to every 3 years [26] . For patients with a non-CDKN2a FPC background, the screening can also begin at the age of 50 years with a frequency of every 3 years unless abnormalities are detected while screening [96] .
So far, it is not clear if this general starting age of 40 years and the frequency of screening is the best option for all different types of predispositions. As shown for the non-CDKN2a FPC background, the screening methods need to be further studied for each type of predisposition and updated according to findings.
Consequences and Treatment Options
If a precursor lesion or any abnormalities are detected, a decision has to be made on which options and treatments are the best to prevent the further development of PDAC. If surgery is chosen, the total resection of all dangerous, high-risk lesions should be the aim. However, a total or partial pancreatectomy should never be an option for patients with asymptomatic lesions [11] . In cases with hereditary pancreatitis, a total pancreatectomy followed by autoislet transplantation could potentially be a treatment option [97] . After total pancreatectomy, it is important to reduce the symptoms, the risk of cancer and diabetes [80] . So far, there is no clear answer as to which treatment option has the best outcomes after detecting lesions in the pancreas.
Consideration
One inherent risk of these screening programs is an overtreatment of patients, which can have effects on the psychological condition [98, 99] . Additionally, the risk of rising costs without helpful results or benefits due to pancreatic cancer screening programs is possible [100] . Psychoanalytical aspects for participants in screening programs have been studied and show that the distribution of anxiety and depression are similar to those in the normal populations, although a third worry about cancer [101, 102] . This leads to the conclusion that screening in high-risk individuals is feasible and justified [101, 103] .
Costs due to PDAC have to be balanced with those of preventive screening programs and the benefit of patients. In general, the costs for patients with pancreatic cancer involve diagnosis, treatment, hospitalization, and productivity loss [104] [105] [106] . These high costs need to be reduced and be subject to economic evaluation [107, 108] . The costs of these screening programs are affordable with respect to MRI and MRCP for patients with higher risk of development of PDAC, and specialization is important for effectiveness [100, 109] . Nevertheless, it is important to reform the guidelines for screening to be more cost effective [100] .
The screening programs seem to be successful in detecting more PDAC lesions and extending survival [110] . In 3.3% of high-risk individuals, lesions are successfully detected, which indicates promising results [111] . Corral et al. [112] summarized in a metaanalysis that 135 patients at high-risk for pancreatic cancer have to be screened to identify 1 patient with a high-risk pancreatic lesion. Problematically, the diagnostic yield differs greatly among the various screening programs, which is a result of variabilities in included study populations, the age and frequency of screening, screening modalities, and the definition of diagnostic yield [11, 21] . The diagnostic yield can be defined as any cystic lesion or histologically proven high-grade lesions [11] . The ratio of surgical cases (from 1.5-50%; average of 5-20%) is dependent on the diagnostic yield, and this yield influences the histopathological outcome of resected lesions as well as the ratio of unresectable advanced pancreatic cancer lesions, which is under 2.5% shown in an analysis of Matsubayashi et al. [19, 113, 114] . 44 of 92 resected lesions in studies described by Matsbayashi et al. were benign lesions, meaning that treatment was unnecessary, and less than 20% were dangerous lesions defined as borderline precursors and carcinoma in situ (18/92); around a third were pancreatic cancer lesions (29/92) that were not detected at early phase (T1N0M0) [19] . All in all, the screening programs are able to successfully detect dangerous precursor lesions. Nevertheless, guidelines in the context of diagnosis yield and treatment are essential to support the success of the pancreatic screening programs.
Discussion and Conclusions
PDAC with its low incidence and low 5-year survival rate is not an entity for population-based screening, but is essential for screening of high-risk individuals [1, 2, 80] . Screening is useful in the context of monitoring high-risk individuals [21] . Individuals involved in screening programs are defined as people with 2 or more first-degree relatives with pancreatic cancer and also include those with cancer syndromes that are known to raise the risk of developing pancreatic cancer to over 5% [21, 25] . Different hereditary cancer syndromes such as PJS, FAMMM or HBOC and additional environmental risk factors are evaluated in screening [25, 46, 115, 116] .
Families with FPC need to be involved in screening programs with data collection and genetic analysis to update the genes already known to be involved and to find new mutated genes such as PALB2 [21, [117] [118] [119] . Screening is useful not only to generate further knowledge, but also to diagnose high-risk lesions before they become invasive [19] . Lesions that can lead to pancreatic cancer (T1N0M0 Adenocarcinoma, PanINs3a, BD-and MD-IMPN) as well as abnormalities like inflammation are detected in these specialized centers [11, 26, 77, 94] .
Methods such as MRI and EUS are as yet the best options for this screening [91] . Nevertheless, a special focus on the development and origin of pancreatic cancer is important, especially in the context of non-linear development of pancreatic cancer [15, 22, 32, 33] . Although some predispositions are well understood, others are not and thus age and frequency of screening need further investigation [96] . So far, the start of screening is at the age of 40 or 10 years below the age of the youngest affected relative in the family, and a frequency of screening of every 1-3 years [11, 26] .
It is still not clear which option for treatment of screened lesions is the best choice, especially since most of the patients show non-specific symptoms with lesions [21, 120] . Thus, further investigation and reviews of guidelines regarding stratification of patients are required to decide which screening modalities and which consequences and treatment options are the best for each subtype of patient [21] . More detailed knowledge for choosing the best age for, and frequency of, screening as well as treatment options such as total pancreatectomy needs to be generated so that screening programs are efficient and useful for the families involved without overtreatment.
